US EditionPublished • loading... • Updated
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Strong Sell at Zacks Research
Summary by defenseworld.net
1 Articles
1 Articles
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Strong Sell at Zacks Research
Zacks Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a strong sell rating in a report released on Thursday,Zacks.com reports. Other equities research analysts have also issued reports about the stock. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $40.00 to $65.00 in a report on Thursda…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
